Vitrolife AB (VITR) AI Stock Analysis

• Market Cap: kr18.98B
• Dividend Yield: 0.79%
• Average Volume (3M): 156.26K
• Price to Earnings (P/E): 41.7
• Beta (1Y): 0.77
• Revenue Growth: 0.14%
• EPS Growth: N/A
• Country: SE
• Employees: 1,150
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Devices
• EPS (TTM): 0.74
• Shares Outstanding: 135,447,190
• 10 Day Avg. Volume: 175,600
• 30 Day Avg. Volume: 156,262
• PEG Ratio: -13.92
• Price to Book (P/B): 1.53
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 28.92
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr169.00
• Price Target Upside: 20.63% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 63 Neutral
• Price Target: kr151.00 ▲(7.78%Upside)

Vitrolife AB's overall stock score is influenced primarily by its strong financial performance, characterized by healthy profitability margins and low leverage. However, the lack of revenue growth and a slightly high valuation detract from its attractiveness, alongside mixed technical indicators that suggest cautious investor sentiment.

Vitrolife AB Business Overview & Revenue Model

Company Description

Vitrolife AB (VITR) is a Swedish biotechnology company that operates in the field of reproductive health. The company specializes in providing products and services for assisted reproduction, including in vitro fertilization (IVF). Vitrolife's offerings encompass a range of high-quality medical devices, culture media, and genetic testing services, aimed at improving the success rates of fertility treatments. The company serves fertility clinics, hospitals, and research institutions globally, contributing to advancements in reproductive medicine.

How the Company Makes Money

Vitrolife AB generates revenue primarily through the sale of its products and services related to assisted reproductive technologies. Its key revenue streams include the sale of IVF media, disposable devices, time-lapse systems, and other related consumables used in fertility treatments. Additionally, the company provides genetic testing services which are increasingly in demand as part of comprehensive fertility treatment plans. Vitrolife also benefits from strategic partnerships and collaborations with healthcare providers and research institutions, which help expand its market reach and drive sales. The company's global presence and focus on innovation further contribute to its financial performance.

Vitrolife AB Financial Statement Overview

Summary

Vitrolife AB maintains a strong financial position with healthy profitability margins, low leverage, and efficient cash flow management. While growth in revenue and net income has stagnated, the company's stability and cash generation capabilities provide a solid foundation for future growth opportunities. Monitoring revenue growth and profitability will be crucial to sustaining long-term performance.

Income Statement

Vitrolife AB shows strong profitability with a consistent Gross Profit Margin of around 57% in the TTM period. The EBIT and EBITDA margins are healthy, indicating efficient cost management. However, revenue growth is stagnant, and net income has slightly declined in the TTM compared to the previous annual report, signaling potential concerns in sustaining growth momentum.

Balance Sheet

The company's balance sheet reveals a strong equity position with a high Equity Ratio of approximately 79% in the TTM. The Debt-to-Equity ratio is manageable at 0.15, reflecting low leverage and financial stability. However, Return on Equity has slightly declined in the TTM period, suggesting room for improved profitability on equity.

Cash Flow

Vitrolife AB demonstrates robust cash management with a positive Free Cash Flow and a solid Operating Cash Flow to Net Income Ratio of 1.56 in the TTM period. Despite a decrease in Free Cash Flow due to reduced Operating Cash Flow, the company's cash generation capabilities remain strong, supporting its financial health.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.61B	3.51B	3.23B	1.68B	1.25B
Gross Profit	2.14B	1.98B	1.78B	1.05B	767.67M
EBITDA	783.00M	-3.19B	993.00M	579.60M	438.65M
Net Income	513.00M	-3.85B	394.00M	341.00M	286.85M
Balance Sheet
Total Assets	17.45B	16.33B	20.55B	19.43B	2.31B
Cash, Cash Equivalents and Short-Term Investments	1.14B	861.00M	578.00M	630.09M	973.57M
Total Debt	2.09B	2.09B	2.23B	2.48B	62.40M
Total Liabilities	3.81B	3.61B	3.81B	4.09B	288.07M
Stockholders Equity	13.64B	12.72B	16.74B	15.32B	2.01B
Cash Flow
Free Cash Flow	907.00M	638.00M	549.00M	321.86M	336.36M
Operating Cash Flow	907.00M	757.00M	636.00M	384.31M	356.45M
Investing Cash Flow	-377.00M	-124.00M	-144.00M	-6.52B	-20.22M
Financing Cash Flow	-286.00M	-300.00M	-582.00M	5.75B	-26.61M

Vitrolife AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 140.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VITR, the sentiment is Negative. The current price of 140.1 is below the 20-day moving average (MA) of 142.98, below the 50-day MA of 148.56, and below the 200-day MA of 188.82, indicating a bearish trend. The MACD of -0.53 indicates Negative momentum. The RSI at 41.97 is Neutral, neither overbought nor oversold. The STOCH value of 53.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:VITR.

Vitrolife AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BIOA.B	73 Outperform	kr17.18B	19.03	60.96%	―	501.62%	―
BONEX	70 Neutral	kr21.36B	144.31	20.14%	―	44.52%	-49.29%
ALIF.B	66 Neutral	$21.29B	63.14	6.27%	0.43%	4.56%	185.59%
VITR	63 Neutral	kr18.98B	41.70	3.46%	0.79%	0.14%	―
EKTA.B	63 Neutral	kr18.49B	78.03	2.43%	4.98%	-0.57%	-81.80%
XVIVO	60 Neutral	$6.69B	60.07	5.17%	―	17.78%	-7.83%
Sector *	52 Neutral	kr5.53B	10.65	-62.48%	1.95%	25.98%	25.74%

Vitrolife AB Corporate Events

Vitrolife AB Reports Q2 2025 Results Amid Currency Challenges

Vitrolife AB reported a flat growth in local currencies for the second quarter of 2025, with a notable impact from currency fluctuations leading to a 7% decrease in sales in SEK. The company saw a strong performance in its Consumables segment with a 9% growth, while Technologies and Genetics saw declines. Despite the challenging currency environment, Vitrolife acquired a leading stake in AutoIVF and secured a EUR 300 million loan to refinance existing debt and support corporate purposes, indicating strategic moves to strengthen its market position.

Vitrolife AB Invests in AutoIVF to Enhance IVF Accessibility

Vitrolife AB has become a leading investor in AutoIVF, an early-stage MedTech company, to enhance the accessibility and affordability of IVF treatments. This strategic investment supports Vitrolife’s goal of automating the IVF process and building a comprehensive platform for fertility care, potentially impacting the reproductive health industry by decentralizing egg retrieval and improving service efficiency.